Evaluating Pharmacogenomic Variants for Cardiology Therapeutics
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Bleeding
- Ischemic Stroke
- Myocardial Infarction
- Stent Thrombosis
- Thrombosis
- Type
- Interventional
- Phase
- Not Applicable
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentIntervention Model Description: There will be two study arms: Conventional therapy (controls)-treatment with clopidogrel and no pre-emptive genotyping Genotype-guided therapy (experimental) Masking: None (Open Label)Masking Description: This is an open label study.Primary Purpose: Diagnostic
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
The Lighthouse tool incorporates pharmacogenetic (PGx) variants from well-established, evidence-based guidelines to provide personalized drug response profile(s) to guide treatment decisions. The patient specimen is genotyped using a proprietary, carefully curated pharmacogenetic variant panel to de...
The Lighthouse tool incorporates pharmacogenetic (PGx) variants from well-established, evidence-based guidelines to provide personalized drug response profile(s) to guide treatment decisions. The patient specimen is genotyped using a proprietary, carefully curated pharmacogenetic variant panel to determine the individual's phenotype. The Lighthouse report (PGx findings) are provided to the clinician, and a notification is generated when the patient has a genotype with a deleterious drug-metabolizing phenotype. Evaluating the South Texas community for the pilot project will enhance the understanding of the impact of genetic variants on individuals of Hispanic/Latino ancestry, especially as the variants pertain to the efficacy and safety of medications.
Tracking Information
- NCT #
- NCT04702113
- Collaborators
- DHR Health Institute for Research and Development
- Investigators
- Principal Investigator: Herschl Silberman, MD DHR Health Study Director: Humberto Mochizu Kitamayo, MD DHR Health Study Director: Yetunde O Kare Opaneye, MD DHR Health
Get Well Soon